[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1200830A1 - Substituted pyrrolidine-2-carboxamides -2- - Google Patents

Substituted pyrrolidine-2-carboxamides -2-

Info

Publication number
HK1200830A1
HK1200830A1 HK15101410.3A HK15101410A HK1200830A1 HK 1200830 A1 HK1200830 A1 HK 1200830A1 HK 15101410 A HK15101410 A HK 15101410A HK 1200830 A1 HK1200830 A1 HK 1200830A1
Authority
HK
Hong Kong
Prior art keywords
carboxamides
substituted pyrrolidine
pyrrolidine
substituted
Prior art date
Application number
HK15101410.3A
Other languages
English (en)
Chinese (zh)
Inventor
David Joseph Bartkovitz
Xin-Jie Chu
Binh Thanh Vu
Chunlin Zhao
Daniel Fishlock
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1200830A1 publication Critical patent/HK1200830A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15101410.3A 2012-03-15 2015-02-09 Substituted pyrrolidine-2-carboxamides -2- HK1200830A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611200P 2012-03-15 2012-03-15
PCT/EP2013/054920 WO2013135648A1 (en) 2012-03-15 2013-03-12 Substituted pyrrolidine-2-carboxamides

Publications (1)

Publication Number Publication Date
HK1200830A1 true HK1200830A1 (en) 2015-08-14

Family

ID=47844360

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101410.3A HK1200830A1 (en) 2012-03-15 2015-02-09 Substituted pyrrolidine-2-carboxamides -2-

Country Status (28)

Country Link
US (1) US8993614B2 (xx)
EP (1) EP2825528B1 (xx)
JP (1) JP6125546B2 (xx)
KR (1) KR20140138165A (xx)
CN (1) CN104271554B (xx)
AR (1) AR090328A1 (xx)
AU (1) AU2013203662B2 (xx)
BR (1) BR112014018959A8 (xx)
CA (1) CA2860781A1 (xx)
CL (1) CL2014001858A1 (xx)
CO (1) CO6990736A2 (xx)
CR (1) CR20140399A (xx)
DK (1) DK2825528T3 (xx)
EA (1) EA025557B1 (xx)
ES (1) ES2634290T3 (xx)
HK (1) HK1200830A1 (xx)
HU (1) HUE032864T2 (xx)
IL (1) IL234173A (xx)
MX (1) MX2014010942A (xx)
NZ (1) NZ626505A (xx)
PE (1) PE20142185A1 (xx)
PH (1) PH12014501542A1 (xx)
PL (1) PL2825528T3 (xx)
SG (1) SG11201404344XA (xx)
SI (1) SI2825528T1 (xx)
TW (1) TWI586648B (xx)
UA (1) UA113541C2 (xx)
WO (1) WO2013135648A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013269798A1 (en) 2012-05-30 2014-10-02 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
RU2015154097A (ru) * 2013-06-24 2017-07-26 Ф. Хоффманн-Ля Рош Аг Стабильный внутривенный препарат
CA2912547A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR101862955B1 (ko) * 2013-12-05 2018-05-31 에프. 호프만-라 로슈 아게 급성 골수성 백혈병(aml)을 위한 신규한 병용 치료
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
MA39877A (fr) * 2014-04-15 2017-02-22 Hoffmann La Roche Formes solides d'un composé pharmaceutiquement actif
CN106536478A (zh) * 2014-05-22 2017-03-22 悉尼大学 ω‑3类似物
WO2016055497A1 (en) * 2014-10-10 2016-04-14 F. Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
CN104496822B (zh) * 2014-12-15 2016-10-26 扬州三友合成化工有限公司 一种1-氯乙基环己基丙基碳酸酯的制备方法
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
TWI717432B (zh) 2015-12-02 2021-02-01 美商艾吉納斯公司 抗體和使用彼之方法
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
US10471154B2 (en) * 2016-08-08 2019-11-12 Fei Xiao Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
CN107698598B (zh) * 2016-08-08 2019-06-21 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2019125798A1 (en) * 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
CN114230561B (zh) * 2020-09-09 2024-03-19 中国人民解放军海军军医大学 一种mdm2抑制剂类小分子化合物及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
EP0452179B1 (en) 1990-03-28 1996-06-12 Nippon Oil And Fats Company, Limited Polymer-combined drug for gastric treatment and a method for producing the drug
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
WO1995016465A1 (en) 1993-12-14 1995-06-22 Sandoz Ltd. Pharmaceutical compositions containing alkyl polyoxyalkylene carboxylates
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
AU9402198A (en) 1997-09-26 1999-04-23 Becton Dickinson & Company Preparing conjugates using polyethylene glycol linkers
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
JP4317744B2 (ja) 2001-05-30 2009-08-19 ナノキャリア株式会社 高分子化合物末端への導入物結合方法
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
EP3669887A1 (en) 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
JP4954864B2 (ja) 2004-04-01 2012-06-20 カーディオム ファーマ コーポレイション イオンチャネル調節化合物のプロドラッグおよびその使用
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
EP2502941A1 (en) 2004-10-25 2012-09-26 Intezyne Technologies Inc. Heterobifunctional poly (ethylene glycol) and uses thereof
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2861601A1 (en) 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
WO2008109783A2 (en) 2007-03-06 2008-09-12 The Regents Of The University Of California Detecting spin perturbations using magnetic resonance imaging
JP2008308690A (ja) 2007-06-13 2008-12-25 Bio-Cancer Treatment Internatl Ltd ポリ(エチレングリコール)機能性誘導体およびその製造方法
WO2009128789A1 (en) 2008-04-17 2009-10-22 Agency For Science, Technology And Research Vesicles for intracellular drug delivery
WO2009155431A1 (en) 2008-06-18 2009-12-23 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
EP2300514B1 (en) 2008-07-14 2016-03-23 Biocon Limited A method of synthesizing a substantially monodispersed mixture of oligomers
JP5731385B2 (ja) 2008-08-22 2015-06-10 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated ポリマーベンジルカルボネート誘導体
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
WO2010031713A1 (en) 2008-09-18 2010-03-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
WO2010151269A1 (en) 2009-06-26 2010-12-29 Biotic Laboratories, Inc. Para-xylylene based multilayer drug elution devices
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
CN101991860B (zh) 2010-11-08 2013-06-19 中国药科大学 泊洛沙姆-羧酸类药物偶联物及其制备方法与应用
WO2012065022A2 (en) 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
CA2825926A1 (en) 2011-02-02 2012-08-09 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
EP2678042B1 (en) 2011-02-23 2018-05-09 The Board of Trustees of the University of Illionis Amphiphilic dendron-coils, micelles thereof and uses
CN102247602B (zh) 2011-06-13 2013-01-02 中山大学 一种超分子水凝胶双重药物载体及其制备方法和应用
WO2013033476A1 (en) 2011-08-30 2013-03-07 Quanta Biodesign, Ltd. Branched discrette peg constructs
AU2013269798A1 (en) * 2012-05-30 2014-10-02 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
EA201491623A1 (ru) 2014-12-30
SG11201404344XA (en) 2014-10-30
WO2013135648A1 (en) 2013-09-19
AU2013203662B2 (en) 2016-04-14
IL234173A (en) 2017-08-31
EP2825528A1 (en) 2015-01-21
BR112014018959A8 (pt) 2017-07-11
PL2825528T3 (pl) 2017-09-29
AR090328A1 (es) 2014-11-05
US20130244958A1 (en) 2013-09-19
PH12014501542B1 (en) 2014-09-22
SI2825528T1 (sl) 2017-08-31
JP6125546B2 (ja) 2017-05-10
ES2634290T3 (es) 2017-09-27
EA025557B1 (ru) 2017-01-30
CN104271554B (zh) 2016-11-23
US8993614B2 (en) 2015-03-31
AU2013203662A1 (en) 2013-10-03
PH12014501542A1 (en) 2014-09-22
PE20142185A1 (es) 2014-12-29
CN104271554A (zh) 2015-01-07
UA113541C2 (xx) 2017-02-10
JP2015512890A (ja) 2015-04-30
CR20140399A (es) 2014-10-07
CA2860781A1 (en) 2013-09-19
DK2825528T3 (en) 2017-08-14
EP2825528B1 (en) 2017-05-24
CO6990736A2 (es) 2014-07-10
TWI586648B (zh) 2017-06-11
TW201341357A (zh) 2013-10-16
CL2014001858A1 (es) 2014-09-26
MX2014010942A (es) 2014-11-14
HUE032864T2 (en) 2017-11-28
BR112014018959A2 (xx) 2017-06-20
KR20140138165A (ko) 2014-12-03
NZ626505A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
HK1201200A1 (en) Substituted pyrrolidine-2-carboxamides -2-
DK3327112T3 (en) Agse-deficient stamme
HK1200830A1 (en) Substituted pyrrolidine-2-carboxamides -2-
EP2754580A4 (en) DUMP TRUCK
EP2935220A4 (en) PERI-carbinol
HK1206724A1 (en) Substituted benzothienopyrimidines
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
HK1206022A1 (zh) 取代的咪唑並噠嗪
GB201203307D0 (en) Remvox
AU345893S (en) Treehouse
GB201204245D0 (en) MobiKey
GB201204088D0 (en) Tidythatcable
GB201203962D0 (en) Locnlatch
GB201203777D0 (en) Quit-clip
GB201203844D0 (en) Salvacubo
GB201203815D0 (en) Mini-meals
GB201203808D0 (en) MicBooth
GB201203612D0 (en) Ishopfront
GB201203604D0 (en) Envelope-box
GB201203507D0 (en) Keynut
GB201203440D0 (en) Blu-seals
GB201202979D0 (en) Ecotunnel
GB201202916D0 (en) E-Space

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220311